Allergen immunotherapy: immunomodulatory treatment for allergic diseases

References

• Simons Estelle F. Ancestors of Allergy. New York Global Medical Communications Ltd, NY, USA (1994).
   Google Scholar
• Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet814–817 (1911).
   Google Scholar
• Freeman J. ‘Rush inoculation’, with special reference to hay fever treatment. Lancet744–747 (1930).
   Google Scholar
• Noon L. Prophylactic inoculation against hay fever. Lancet1572–1573 (1911).
   Google Scholar
• Ishzaka K, Ishizaka T. Identification of gamma-E antibodies as a carrier of reaginic activity. J. Immunol.99, 1187–1199 (1967).
   PubMed Web of Science ®Google Scholar
• Durham SR, Varney VA, Gaga M et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin. Exp. Allergy29(11), 1490–1496 (1999).
   PubMed Web of Science ®Google Scholar
• Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy61(2), 151–165 (2006).
   PubMed Web of Science ®Google Scholar
• Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin. Exp. Allergy23(8), 647–660 (1993).
   PubMed Web of Science ®Google Scholar
• Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin. Allergy17(5), 459–468 (1987).
   PubMedGoogle Scholar
• Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J. Allergy Clin. Immunol.113(6), 1025–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J. Allergy Clin. Immunol.112(5), 915–922 (2003).
   PubMed Web of Science ®Google Scholar
• Shamji MH, Larche M, Francis JN, Durham SR. Validation of a functional assay of IgE-facilitated CD23-dependent allergen binding to B cells to monitor clinical efficacy of immunotherapy (abstract). J. Allergy Clin. Immunol.117(2), S330 (2006).
   Google Scholar
• Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β; the role of T regulatory cells. Immunology117(4), 433–442 (2006).
   PubMed Web of Science ®Google Scholar
• Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol.111(6), 1255–1261 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcock LK, Paraskavopoulos G, Till SJ, Durham SR. Induction of IL-10 occurs early and precedes serum IgG blocking activity during a cluster regimen of grass pollen immunotherapy (abstract). J. Allergy Clin. Immunol.117(2), 330 (2006).
   Google Scholar
• Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy55(5), 455–462 (2000).
   PubMed Web of Science ®Google Scholar
• Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy36(4), 465–474 (2006).
   PubMed Web of Science ®Google Scholar
• Ross RN, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis. Clin. Ther.22, 342–350 (2000).
   PubMed Web of Science ®Google Scholar
• Ross RN, Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther.22, 351–358 (2000).
   PubMed Web of Science ®Google Scholar
• Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy61(2), 202–205 (2006).
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am. J. Respir. Crit. Care Med.151, 969–974 (1995).
   PubMed Web of Science ®Google Scholar
• Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin. Ther.22, 329–341 (2000).
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev.4, CD001186 (2003).
   Google Scholar
• Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J. Allergy Clin. Immunol.113(4), 643–649 (2004).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol.108(Suppl. 5), S147–S334 (2001).
   PubMed Web of Science ®Google Scholar
• Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy61(2), 198–201 (2006).
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Morgan WJ, Zeiger RS et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med.354(19), 1985–1997 (2006).
   PubMed Web of Science ®Google Scholar
• Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N. Engl. J. Med.343(15), 1054–1063 (2000).
   PubMed Web of Science ®Google Scholar
• Lent AM HR, Sills M, Schmidt K, Efaw B, Lebo TS. Immunological response to administration of standardized dog allergen extract at differing doses (abstract). J. Allergy Clin. Immunol.117(2), S330 (2006).
   Google Scholar
• Nanda A, O’Connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J. Allergy Clin. Immunol.114(6), 1339–1344 (2004).
   PubMed Web of Science ®Google Scholar
• Ewbank P, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind placebo-controlled immunotherapy dose-response study with standardized cat extract. J. Allergy Clin. Immunol.111, 155–161 (2003).
   PubMed Web of Science ®Google Scholar
• Creticos P, Adkinson NF Jr, Kagey-Sobotka A et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J. Clin. Invest.76, 2247–2253 (1985).
   PubMed Web of Science ®Google Scholar
• Bosquet J, Soussana M, Michel F-B. Double-blind placebo-controlled immunotherapy grass-pollen allergoids IV. Compaarison of the safety and efficacy of two doses of a high-molecular-weight allergoid. Immunotherapy. J. Allergy Clin. Immunol.85(2), 490–497 (1990).
   PubMed Web of Science ®Google Scholar
• Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.117, 319–325 (2006).
   PubMed Web of Science ®Google Scholar
• Haugaard L, Dahl RJ, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J. Allergy Clin. Immunol.91, 709–722 (1993).
   PubMed Web of Science ®Google Scholar
• Kohno Y, Minoguchi K, Oda N et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J. Allergy Clin. Immunol.102(6 Pt 1), 927–934 (1998).
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med.341(7), 468–475 (1999).
   PubMed Web of Science ®Google Scholar
• Des Roches A, Paradis L, Knani J et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy51(6), 430–433 (1996).
   PubMed Web of Science ®Google Scholar
• Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol.109(2), 251–256 (2002).
   PubMed Web of Science ®Google Scholar
• Valovirta E, Niggemann B, Dreborg S et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study. J. Allergy Clin. Immunol.117(3) (2006) (Abstract).
   Google Scholar
• Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarva M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir. Res.6, 153 (2005).
   PubMed Web of Science ®Google Scholar
• Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.114(4), 851–857 (2004).
   PubMed Web of Science ®Google Scholar
• Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol.99(4), 450–453 (1997).
   PubMed Web of Science ®Google Scholar
• Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy31(9), 1392–1397 (2001).
   PubMed Web of Science ®Google Scholar
• Purello-D’Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy31(8), 1295–1302 (2001).
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy59(11), 1205–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann. Allergy73(5), 409–418 (1994).
   PubMedGoogle Scholar
• Tabar AI, Echechipia S, Garcia BE et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J. Allergy Clin. Immunol.116(1), 109–118 (2005).
   PubMed Web of Science ®Google Scholar
• Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J. Allergy Clin. Immunol.97(6), 1207–1213 (1996).
   PubMed Web of Science ®Google Scholar
• Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J. Allergy Clin. Immunol.106(5), 840–843 (2000).
   PubMed Web of Science ®Google Scholar
• Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann. Allergy Asthma Immunol.92(2), 225–227 (2004).
   PubMed Web of Science ®Google Scholar
• Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol.87(1 Suppl. 1), 47–55 (2001).
   PubMed Web of Science ®Google Scholar
• Parmiani S, Fernandez Tavora L, Moreno C, Guardia P, Rico P. Clustered schedules in allergen-specific immunotherapy. Allergol. Immunopathol. (Madr.)30(5), 283–291 (2002).
   PubMedGoogle Scholar
• Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann. Allergy Asthma Immunol.76(2), 175–180 (1996).
   PubMed Web of Science ®Google Scholar
• Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J. Allergy Clin. Immunol.117(1), 169–175 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J. Allergy Clin. Immunol.113(6), 1129–1136 (2004).
   PubMed Web of Science ®Google Scholar
• Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J. Allergy Clin. Immunol.92(1 Pt 1), 6–15 (1993).
   PubMed Web of Science ®Google Scholar
• Lockey RF. Adverse reactions associated with skin testing and immunotherapy. Allergy Proc.16(6), 293–296 (1995).
   PubMedGoogle Scholar
• Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allerg. Immunol. (Paris)36(2), 52–55 (2004).
   Google Scholar
• Casale TB, Busse WW, Kline JN et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol.117(1), 134–140 (2006).
   PubMed Web of Science ®Google Scholar
• Bagnasco M, Mariani G, Passalacqua G et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J. Allergy Clin. Immunol.100(1), 122–129 (1997).
   PubMed Web of Science ®Google Scholar
• Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol.117(5), 1021–1035 (2006).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Fenoglio D, Cirillo I et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma Immunol.95(1), 38–44 (2005).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Fenoglio D, Cirillo I, Milanese M, Minuti P. Sublingual immunotherapy and regulatory T cells. Allergy61(4), 511–513 (2006).
   PubMedGoogle Scholar
• Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy35(5), 565–571 (2005).
   PubMed Web of Science ®Google Scholar
• Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol. Clin. Immunol.15, 9–16 (2005).
   Google Scholar
• Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy60(1), 4–12 (2005).
   PubMed Web of Science ®Google Scholar
• Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy33(2), 206–210 (2003).
   PubMed Web of Science ®Google Scholar
• Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J. Allergy Clin. Immunol.114(4), 831–837 (2004).
   PubMed Web of Science ®Google Scholar
• Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy59(1), 45–53 (2004).
   PubMed Web of Science ®Google Scholar
• Andre C, Perrin-Fayolle M, Grosclaude M et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int. Arch. Allergy Immunol.131(2), 111–118 (2003).
   PubMed Web of Science ®Google Scholar
• Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev. Vaccines4(6), 881–889 (2005).
   PubMed Web of Science ®Google Scholar
• Schramm G, Kahlert H, Suck R et al. “Allergen engineering”: variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol.162(4), 2406–2414 (1999).
   PubMed Web of Science ®Google Scholar
• Smith AM, Chapman MD, Taketomi EA, Platts-Mills TA, Sung SS. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J. Allergy Clin. Immunol.101(3), 423–425 (1998).
   PubMed Web of Science ®Google Scholar
• Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy60(10), 1269–1274 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander C, Ying S, B Kay A, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy35(1), 52–58 (2005).
   PubMed Web of Science ®Google Scholar
• Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet360, 47–53 (2002).
   PubMed Web of Science ®Google Scholar
• Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol.111(4), 854–861 (2003).
   PubMed Web of Science ®Google Scholar
• Muller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol.101(6 Pt 1), 747–754 (1998).
   Google Scholar
• Immonen A, Farci S, Taivainen A et al. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J. Immunol.175(6), 3614–3620 (2005).
   PubMed Web of Science ®Google Scholar
• Kwon SS, Kim NS, Yoo TJ. Vaccination with DNA encoding human T-cell epitopes suppresses Der p induced allergic responses in mice. J. Asthma42(2), 119–125 (2005).
   PubMed Web of Science ®Google Scholar
• Chapman MD, Smith AM, Vailes LD, Arruda LK, Dhanaraj V, Pomes A. Recombinant allergens for diagnosis and therapy of allergic disease. J. Allergy Clin. Immunol.106(3), 409–418 (2000).
   PubMed Web of Science ®Google Scholar
• Bohle B, Breitwieser A, Zwolfer B et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol.172(11), 6642–6648 (2004).
   PubMed Web of Science ®Google Scholar
• Nopp A, Hallden G, Lundahl J et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J. Allergy Clin. Immunol.106(1 Pt 1), 101–109 (2000).
   PubMed Web of Science ®Google Scholar
• Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin. Exp. Allergy33(10), 1330–1335 (2003).
   PubMed Web of Science ®Google Scholar
• Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol.113(6), 1144–1151 (2004).
   PubMed Web of Science ®Google Scholar
• Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol.113(2), 235–241 (2004).
   PubMed Web of Science ®Google Scholar
• Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol.90(1 Suppl. 1), 1–40 (2003).
   Google Scholar
• Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27–29. Allergy53(44 Suppl.), 1–42 (1997).
   Google Scholar